Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study

被引:8
作者
Patel, Priya [1 ,2 ]
Lavoratore, Sara R. [3 ]
Flank, Jacqueline [1 ]
Kemp, Meaghan [1 ]
Vennettilli, Ashlee [4 ]
Vol, Helen [1 ]
Taylor, Tracey [1 ]
Zelunka, Elyse [1 ]
Maloney, Anne Marie [5 ]
Nathan, Paul C. [4 ,6 ,7 ]
Dupuis, L. Lee [1 ,2 ,4 ]
机构
[1] Hosp Sick Children, Dept Pharm, Toronto, ON, Canada
[2] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[3] Rideau Community Hlth Serv, Smiths Falls, ON, Canada
[4] Hosp Sick Children, Res Inst, Child Hlth Evaluat Sci, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
[5] Hosp Sick Children, Dept Nursing, Toronto, ON, Canada
[6] Hosp Sick Children, Dept Paediat, Toronto, ON, Canada
[7] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
关键词
Chemotherapy-induced nausea and vomiting; Emetogenicity; Etoposide; Ifosfamide; Pediatrics; CHILDREN; GUIDELINE; PREVENTION;
D O I
10.1007/s00520-019-04903-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Little evidence exists regarding the emetogenicity of chemotherapy in pediatric patients. This study describes the prevalence of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving etoposide plus ifosfamide over 5 days, a common pediatric regimen. Methods English-speaking, non-chemotherapy-naive patients aged 4 to 18 years about to receive etoposide 100 mg/m(2)/day plus ifosfamide 1800 mg/m(2)/day over 5 days participated. Antiemetic prophylaxis was determined by each patient's care team. Emetic episodes were recorded and nausea severity was assessed by patients beginning with the first chemotherapy dose, continuing until 24 h after the last chemotherapy dose (acute phase) and ending 7 days later (delayed phase). The proportion of patients experiencing complete acute CINV control (no nausea, no vomiting, and no retching), the primary study endpoint, was described. The prevalence of complete chemotherapy-induced vomiting (CIV) and chemotherapy-induced nausea (CIN) during the acute, delayed, and overall (acute plus delayed) phases; complete delayed and overall CINV control; and anticipatory CINV were also determined. Results Twenty-four patients participated; acute CINV was evaluable in 22. Most (75%; 18/24) received a 5-HT3 antagonist plus dexamethasone for antiemetic prophylaxis. Few (23%; 5/22) experienced complete acute CINV control. Complete acute CIV and CIN control were experienced by 57% (13/23) and 27% (6/22) of patients, respectively. Complete delayed CINV, CIV, and CIN control rates were 42% (8/19), 70% (14/20), and 42% (8/19), respectively. Conclusions Our findings support the classification of etoposide 100 mg/m(2)/day plus ifosfamide 1800 mg/m(2)/day IV over 5 days as highly emetogenic. This information will optimize antiemetic prophylaxis selection and CINV control in pediatric patients.
引用
收藏
页码:933 / 938
页数:6
相关论文
共 19 条
[1]   ORAL ONDANSETRON - AN EFFECTIVE AMBULATORY COMPLEMENT TO INTRAVENOUS ONDANSETRON IN THE CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN CHILDREN [J].
COHEN, IJ ;
ZEHAVI, N ;
BUCHWALD, I ;
YANIV, Y ;
GOSHEN, Y ;
KAPLINSKY, C ;
ZAIZOV, R .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1995, 12 (01) :67-72
[2]  
Dupuis LL, 2018, PEDIATR BLOOD CANCER, V65, pS33
[3]   Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents [J].
Dupuis, L. Lee ;
Taddio, Anna ;
Kerr, Elizabeth N. ;
Kelly, Andrea ;
MacKeigan, Linda .
PHARMACOTHERAPY, 2006, 26 (09) :1221-1231
[4]   Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy [J].
Dupuis, L. Lee ;
Tamura, Roy N. ;
Kelly, Kara M. ;
Krischer, Jeffrey P. ;
Langevin, Anne-Marie ;
Chen, Lu ;
Kolb, E. Anders ;
Ullrich, Nicole J. ;
Sahler, Olle Jane Z. ;
Hendershot, Eleanor ;
Stratton, Ann ;
Sung, Lillian ;
McLean, Thomas W. .
PEDIATRIC BLOOD & CANCER, 2019, 66 (04)
[5]   2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children [J].
Dupuis, L. Lee ;
Sung, Lillian ;
Molassiotis, Alexander ;
Orsey, Andrea D. ;
Tissing, Wim ;
van de Wetering, Marianne .
SUPPORTIVE CARE IN CANCER, 2017, 25 (01) :323-331
[6]   Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients [J].
Dupuis, L. Lee ;
Boodhan, Sabrina ;
Holdsworth, Mark ;
Robinson, Paula D. ;
Hain, Richard ;
Portwine, Carol ;
O'Shaughnessy, Erin ;
Sung, Lillian .
PEDIATRIC BLOOD & CANCER, 2013, 60 (07) :1073-1082
[7]   Symptom assessment in children receiving cancer therapy: the parents' perspective [J].
Dupuis, L. Lee ;
Milne-Wren, Cindy ;
Cassidy, Marilyn ;
Barrera, Maru ;
Portwine, Carol ;
Johnston, Donna L. ;
Silva, Mariana Pradier ;
Sibbald, Cathryn ;
Leaker, Michael ;
Routh, Stacey ;
Sung, Lillian .
SUPPORTIVE CARE IN CANCER, 2010, 18 (03) :281-299
[8]  
Ettinger DS, 2018, NCCN GUIDELINES VERS
[9]   Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study [J].
Gilmore, James W. ;
Peacock, Nancy W. ;
Gu, Anna ;
Szabo, Stephen ;
Rammage, Melissa ;
Sharpe, Joyce ;
Haislip, Sally T. ;
Perry, Toni ;
Boozan, Tim L. ;
Meador, Katherine ;
Cao, Xiting ;
Burke, Thomas A. .
JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (01) :68-+
[10]   Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting [J].
Heo, Young-A ;
Deeks, Emma D. .
DRUGS, 2017, 77 (15) :1687-1694